Clinical trials: Gastrointestinal Neoplasm Malignant
Carcinoma, Non-Small-Cell Lung, Cancer of the Gastrointestinal Tract
Effect of Qigong Therapy in Patients With Advanced Lung and Gastrointestinal Cancer Undergoing Chemotherapy
Cancer patients face a number of symptoms related to treatment or disease which may impair quality of life, such as decreased functional capacity, fatigue, nausea an vomiting, distress, depression and unmet psychological needs.
- Trial name
- NCT01374100
- Testing
- Standard Exercise, Qigong Exercise
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- McGill University
Biliary Tract Cancer, Cholangiocarcinoma
Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer
The investigators design a prospective clinical study to explore the efficacy and safety of apatinib plus camrelizumab in pretreated patients with advanced biliary tract malignant tumors and to analyze potential biomarkers of…
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Biomarker, Hepatobiliary Neoplasm
- Trial name
- ACABC (NCT04642664)
- Testing
- Apatinib plus Camrelizumab
- Where
- 2 sites in China
- Volunteers
- 22 people
- Sponsor
- Peking Union Medical College Hospital
General Anesthesia Gastrointestinal Cancer Surgery
The Safety and Effectiveness of NEPA in Preventing Postoperative Nausea and Vomiting After General Anesthesia Gastrointestinal Cancer Surgery: A Single-Center Retrospective Study
The rapid progress of multiple antiemetic regimens ensures that patients can receive full dose chemotherapy, however, there are still a large number of unmet clinical needs in patient evaluation and treatment.
- Trial name
- NCT06417567
- Testing
- NEPA
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Neuroendocrine Tumor, Malignant, Neuroendocrine Tumor Gastrointestinal, Hormone-Secreting
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
This study is designed to identify the best tolerated doses of [131]Iodine-MIBG and [90]Yttrium-DOTATOC when co-administered to treat midgut neuroendocrine tumors.
- Trial name
- NCT03044977
- Testing
- 90Y-DOTA-3-Tyr-Octreotide, 131I-MIBG
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- David Bushnell
Malignant Digestive System Neoplasm
Evaluation of Portal Vein Stenting in Patients With Portal Vein Stenosis and Gastrointestinal Cancers
This study collects information about the safety and effect of portal vein stenting in gastrointestinal cancer patients with portal vein stenosis.
- Trial name
- NCT04629677
- Testing
- Electronic Health Record Review, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Neoplasm, Colon Neoplasm
A Study of MLN8054 in Patients With Advanced Solid Tumors
The purpose of this study is to determine (1) The side effects or toxicities of MLN8054;(2) The highest dose where side effects or toxicities are not too severe; (3) How MLN8054 is absorbed into the general blood circulation and…
- Conditions
- Breast Neoplasm, Colon Neoplasm, Pancreatic Neoplasm, Bladder Neoplasm
- Trial name
- NCT00249301
- Testing
- MLN8054
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Breast Cancer, Non-small Cell Lung Cancer
Integrated Molecular Profiling in Advanced Cancers Trial
Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient.
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Genitourinary Cancer
- Trial name
- IMPACT (NCT01505400)
- Where
- Canada
- Volunteers
- 3,026 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer, Solid Cancers
A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CEA-positive advanced malignant solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
- Conditions
- Colorectal Cancer, Solid Cancers, Gastric Cancer
- Trial name
- NCT05396300
- Testing
- Intraperitoneal infusion of FAST CEA-targeted CAR-T, CEA CAR-T cells
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Weijia Fang, MD
Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma
CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
This phase Ib/II trial studies the side effects and best dose of CMP-001 and how well it works when given together with INCAGN01949 in treating patients with stage IV pancreatic cancer and other cancers except melanoma.
- Conditions
- Locally Advanced Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm
- Trial name
- NCT04387071
- Testing
- Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949, VLP-encapsulated TLR9 Agonist CMP-001
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- University of Southern California
Pancreas Neoplasms, Liver Metastasis
Surgical Approach for Adenocarcinoma of the Pancreas With Synchronous Liver Metastases
The study focuses on patients with synchronous liver metastasis from pancreatic adenocarcinoma that underwent both pancreatic and liver resection.
- Conditions
- Pancreas Neoplasms, Liver Metastasis, Pancreas Ductal Adenocarcinoma, Surgery of the Pancreatic Head
- Trial name
- NCT06980792
- Testing
- Pancreatectomy and liver resection, Chemotherapy
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Stomach Cancer, Neoplasm Metastasis
Metastatic Gastric Cancer FFCD 03-07
The purpose of this study is to compare the effectiveness of 2 different sequences of polychemotherapy among carrying patients of a adenocarcinoma of the stomach or cardia locally advanced or metastatic.
- Trial name
- NCT00374036
- Testing
- ECC, FOLFIRI
- Where
- France
- Volunteers
- 416 people
- Sponsor
- University Hospital, Toulouse
Metastatic Malignant Neoplasm
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors.
- Trial name
- NCT05958199
- Testing
- NPX267
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- NextPoint Therapeutics, Inc.
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer
- Trial name
- MDX1106-01 (NCT00441337)
- Testing
- MDX-1106
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Colorectal Cancer
A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice
This study is a multi-centre retrospective observational research study which will be conducted in UK centres with specialised liver surgical services.
- Trial name
- RESECT (NCT01460745)
- Where
- 5 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Gastroesophageal Adenocarcinoma, First Line Therapy
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
The ZANGEA trial is a open-label, single arm, multicenter phase II trial assessing the efficacy of zanidatamab in combination with pembrolizumab and chemotherapy in patients with metastatic gastroesophageal adenocarcinoma (GEA).
- Conditions
- Gastroesophageal Adenocarcinoma, First Line Therapy, HER2 + Gastric Cancer, PDL-1
- Trial name
- ZANGEA (NCT07176312)
- Testing
- Zanidatamab, Pembrolizumab, mFOLFOX
- Where
- 20 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Colorectal Cancer, Adenoma Colon
Liquid Biopsy and Machine Learning for Early Colorectal Cancer, Adenomas, Lynch Cancers, and Residual Disease Detection
This is an multicenter study that will test the diagnostic accuracy of a blood test (i.e., a liquid biopsy) for the diagnosis of colorectal cancer (CRC), advanced adenomas (AAs), as well as Lynch-syndrome associated cancers.
- Conditions
- Colorectal Cancer, Adenoma Colon, Adenoma Colon Polyp, Colon Adenoma
- Trial name
- BEACON (NCT07450612)
- Testing
- BEACON
- Where
- 4 sites in Italy
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- San Raffaele University
Carcinoma, Hepatocellular, Hepatobiliary Neoplasm
Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
To determine the efficacy and toxicity of TACE combined with SBRT
- Conditions
- Carcinoma, Hepatocellular, Hepatobiliary Neoplasm, Liver Carcinoma
- Trial name
- NCT01020812
- Testing
- TACE, SBRT
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
Stomach Neoplasm
The Origin of Infrapyloric Artery
Infrapyloric artery(IPA) is of great importance for gastric cancer patients. According to previous study, the origin of IPA varies greatly among different studies.
- Trial name
- IPA-Origin (NCT03071237)
- Testing
- Gastrectomy
- Where
- China
- Volunteers
- 429 people
- Sponsor
- Peking University
Relapsed Malignant Solid Neoplasm
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced malignancies will be done to assess AUR107 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.
- Trial name
- NCT05865002
- Testing
- AUR107
- Where
- 37 sites in India
- Volunteers
- 50 people
- Sponsor
- Aurigene Discovery Technologies Limited
Adenocarcinoma, Circulating Tumor Cells
CTC Pancreatic Adenocarcinoma
Proportion of circulating tumor cells (CTC) in the postoperative phase after curative tumor removal of pancreatic cancer will be determined and correlated to the accordance of anesthesia (desflurane versus propofol)
- Conditions
- Adenocarcinoma, Circulating Tumor Cells, Pancreatic Neoplasms
- Trial name
- NCT02335151
- Testing
- Desflurane
- Where
- 4 sites in Switzerland
- Volunteers
- 86 people
- Sponsor
- University of Zurich
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.